menu
    • menu

    Company profile for Jaguar Health

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is appr...
    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Jaguar HealthUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    201 Mission Street, Suite 2375, San Francisco, CA 94105, US
    Telephone
    Telephone
    (415) 371-8300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://jaguar.health/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/jaguar-health/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jaguar Health Receives $240K FDA Grant For Canalevia-CA1
    Jaguar Health Receives $240K FDA Grant For Canalevia-CA1

    02 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-02/jaguar-health-awarded-240-000-fda-grant-in-support-of-canalevia-ca1-for-treatment-of-chemotherapy-i

    PHARMIWEB
    02 Jan 2026
    Share Share
    Jaguar Health Announces Abstract Submission for Preliminary Data
    Jaguar Health Announces Abstract Submission for Preliminary Data

    15 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-15/jaguar-health-announces-abstract-submission-for-preliminary-data-from-us-investigator-initiated-tria

    PHARMIWEB
    15 Dec 2025
    Share Share
    FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea
    FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea

    10 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-10/fda-approves-renewal-of-canalevia-ca1-jaguar-healths-drug-for-chemotherapy-induced-diarrhea-cid

    PHARMIWEB
    10 Dec 2025
    Share Share
    Jaguar Health Approves All Proposals at December 2025 Meeting
    Jaguar Health Approves All Proposals at December 2025 Meeting

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/jaguar-health-reports-approval-of-all-proposals-at-december-2025-special-meeting-of-stockholders

    PHARMIWEB
    08 Dec 2025
    Share Share
    Jaguar Health Files EMA Application for Canalevia in Dogs
    Jaguar Health Files EMA Application for Canalevia in Dogs

    02 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-02/jaguar-health-makes-submission-to-ema-regarding-eu-approval-pathway-for-canalevia-for-general-diarrh

    PHARMIWEB
    02 Dec 2025
    Share Share
    Jaguar Health Strengthens Global IP With New Crofelemer Patent
    Jaguar Health Strengthens Global IP With New Crofelemer Patent

    24 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-24/jaguar-health-secures-new-patent-for-crofelemer-in-short-bowel-syndrome-strengthening-global-ip-pos

    PHARMIWEB
    24 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search